{"entity":{"id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","aka":[],"tldr":"A phase 3 trial of TAR-210 and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer is a phase 3 interventional study registered as NCT06319820 by Janssen Research & Development, LLC, with 641 participants planned, started 2024-04-18 and due to reach its primary completion in 2028-06-28. Interventions recorded: TAR-210, Gemcitabine and MMC.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06319820","url":"https://clinicaltrials.gov/study/NCT06319820"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["tar-210","gemcitabine"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06319820","phase":"3","setting":"A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations","sponsor":"Janssen Research & Development, LLC","enrolled":641,"outcomes":[]},"route":"/trials/nct06319820/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"tar-210","kind":"drug","name":"TAR-210","route":"/drugs/tar-210/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}